Congress is out of session until Monday, November 9 for the midterm campaign. No new roll-call votes until then; the last were the House on Sep 16 and the Senate on Sep 30.

S. 607 · 118th Congress · Health

EFFECTIVE Act

Died in committee113 words Introduced Mar 1, 2023 · Latest action Mar 1, 2023

FollowRead the text
How far it has goneStopped at 2 of 6 · Died in committee
  1. IntroducedMar 1, 2023 Done
  2. CommitteeDied Jan 3, 2025 Stopped here
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

What it does

This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug (i.e., opioid medication) upon a determination that the drug does not provide a significant advantage with respect to safety or effectiveness as compared to other drugs.

Congressional Research Service · summary of “Introduced in Senate” version · Mar 1, 2023

Who lobbies on it

No lobbying filing on file names S. 607.

Organizations that named S. 607 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.

Actions

2 actions · newest first
  1. Mar 1, 2023Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
  2. Mar 1, 2023Introduced in Senate